abstract |
The present invention comprises an RNA vaccine comprising at least one RNA comprising at least one open reading frame (ORF) encoding at least one antigen, and at least one PD-1 pathway inhibitor, preferably PD- It relates to a vaccine / inhibitor combination comprising a composition comprising one receptor or its ligands PD-L1 and PD-L2. The present invention further relates to pharmaceutical compositions and parts kits comprising the components of the vaccine / inhibitor combination. The invention further relates to the medical use of the vaccine / inhibitor combination, the pharmaceutical composition and the kit of parts comprising the vaccine / inhibitor combination, in particular a tumor or cancer disease or It relates to medical use for the prevention or treatment of infectious diseases. The invention further relates to the use of RNA vaccines in therapy in combination with inhibitors of PD-1 pathway and the use of PD-1 pathway inhibitors in therapy in combination with RNA vaccines. |